Article Information
History
- March 20, 2020.
Article Versions
- You are currently viewing Version 1 of this article (March 20, 2020 - 07:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Drifa Belhadi, MSc#,*,1,2,
- Nathan Peiffer-Smadja, MD*,1,3,
- Yazdan Yazdanpanah, PhD1,3,
- France Mentré, PhD1,2 and
- Cédric Laouénan, PhD1,2
- 1Université de Paris, IAME, INSERM, F-75018 Paris, France
- 2Département d’Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat – Claude-Bernard, AP-HP, 75018 Paris, France
- 3Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France
- ↵#Corresponding author; email: drifa.belhadi{at}aphp.fr
Posted March 20, 2020.
A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19
